Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cusatuzumab - argenx

Drug Profile

Cusatuzumab - argenx

Alternative Names: Anti-CD70 SIMPLE Antibody; ARGX-110; JNJ 74494550; JNJ-4550

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator arGEN-X
  • Developer argenx; Cilag GmbH International
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD70 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Cutaneous T-cell lymphoma; Myelodysplastic syndromes
  • Phase I/II Haematological malignancies; Solid tumours
  • No development reported Autoimmune disorders; Nasopharyngeal cancer

Most Recent Events

  • 28 May 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, First-line therapy) in Japan (IV)
  • 28 May 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, First-line therapy) in Japan (IV)
  • 27 Mar 2023 Cusatuzumab licensed to OncoVerity worldwide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top